Mycobacterial lipopeptides elicit CD4+ CTLs in Mycobacterium tuberculosis-infected humans

Journal of Immunology

Volumn 180, Issue 5, 2008, Pages 3436-3446

  Bastian, Max ^a   Braun, Tobias ^b   Bruns, Heiko ^a   Röllinghoff, Martin ^b   Stenger, Steffen ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BCG VACCINE; CD4 ANTIGEN; CD45RO ANTIGEN; CELL EXTRACT; CHEMOKINE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; CHLOROFORM METHANOL EXTRACT; CYTOKINE; GAMMA INTERFERON; GLYCOLIPID; LIPOPEPTIDE; MACROPHAGE ACTIVATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEINASE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; HLA D ANTIGEN; LIPOPROTEIN; PEPTIDE;

ANTIGEN EXPRESSION; ARTICLE; BACTERICIDAL ACTIVITY; BIOLOGICAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL WALL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEMORY CELL; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; TUBERCULOSIS; ANTIGEN PRESENTATION; CELL CULTURE; CHEMISTRY; CYTOTOXICITY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION;

ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; CD4-POSITIVE T-LYMPHOCYTES; CELL WALL; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HLA-D ANTIGENS; HUMANS; HYDROPHOBICITY; IMMUNOPHENOTYPING; LIPOPROTEINS; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; PEPTIDES; T-LYMPHOCYTE SUBSETS; TUBERCULOSIS;

EID: 49149109918     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.5.3436     Document Type: Article

References (100)

1. Anonymous. 2007. Global Tuberculosis Control: WHO Report 2007. World Health Organization, Geneva, pp. 1-2.
2. Friedland, G. 2007. Tuberculosis, drug resistance, and HIV/AIDS: a triple threat. Curr. Infect. Dis. Rep. 9: 252-261.
3. Anonymous. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55: 301-305.
4. Brewer, T. F. 2000. Preventing tuberculosis with bacillus Calmette-Guérin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 31(Suppl. 3): 64-67.
5. Trunz, B. B., P. Fine, and C. Dye. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173-1180.
6. Horwitz, M. A., and G. Harth. 2003. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71: 1672-1679.
7. Grode, L., P. Seiler, S. Baumann, J. Hess, V. Brinkmann, E. A. Nasser, P. Mann, C. Goosmann, S. Bandermann, D. Smith, et al. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J. Clin. Invest. 115: 2472-2479.
8. Olsen, A. W., A. Williams, L. M. Okkels, G. Hatch, and P. Andersen. 2004. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect. Immun. 72: 6148-6150.
9. Langermans, J. A., T. M. Doherty, R. A. Vervenne, T. van der Laan, K. Lyashchenko, R. Greenwald, E. M. Agger, C. Aagaard, H. Weiler, D. van Soolingen, et al. 2005. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 23: 2740-2750.
10. Brandt, L., Y. A. Skeiky, M. R. Alderson, Y. Lobet, W. Dalemans, O. C. Turner, R. J. Basaraba, A. A. Izzo, T. M. Lasco, P. L. Chapman, et al. 2004. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72: 6622-6632.
11. McShane, H., A. A. Pathan, C. R. Sander, S. M. Keating, S. C. Gilbert, K. Huygen, H. A. Fletcher, and A. V. Hill. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10: 1240-1244.
12. Kaufmann, S. H., and A. J. McMichael. 2005. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med. 11: S33-S44.
13. Boom, W. H., D. H. Canaday, S. A. Fulton, A. J. Gehring, R. E. Rojas, and M. Torres. 2003. Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis 83: 98-106.
14. Kaufmann, S. H. 2005. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26: 660-667.
15. Chen, Z. W. 2005. Immune regulation of γδ T cell responses in mycobacterial infections. Clin. Immunol. 116: 202-207.
16. Behar, S. M., and S. A. Porcelli. 2007. CD1-restricted T cells in host defense to infectious diseases. Curr. Top. Microbiol. Immunol. 314: 215-250.
17. + T cells. Nature 372: 691-694.
18. Sieling, P. A., D. Chatterjee, S. A. Porcelli, T. I. Prigozy, R. J. Mazzaccaro, T. Soriano, B. R. Bloom, M. B. Brenner, M. Kronenberg, P. J. Brennan, et al. 1995. CD1-restricted T cell recognition of microbial lipoglycan antigens. Science 269: 227-230.
19. - restricted T cells. Science 278: 283-286.
20. Matsunaga, I., A. Bhatt, D. C. Young, T. Y. Cheng, S. J. Eyles, G. S. Besra, V. Briken, S. A. Porcelli, C. E. Costello, W. R. Jacobs, Jr., and D. B. Moody. 2004. Mycobacterium tuberculosis pks12 produces a novel polyketide presented by CD1c to T cells. J. Exp. Med. 200: 1559-1569.
21. Moody, D. B., D. C. Young, T. Y. Cheng, J. P. Rosat, C. Roura-Mir, P. B. O'Connor, D. M. Zajonc, A. Walz, M. J. Miller, S. B. Levery, et al. 2004. T cell activation by lipopeptide antigens. Science 303: 527-531.
22. Gilleron, M., S. Stenger, Z. Mazorra, F. Wittke, S. Mariotti, G. Bohmer, J. Prandi, L. Mori, G. Puzo, and G. De Libero. 2004. Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. J. Exp. Med. 199: 649-659.
23. - T lymphocytes to a microbial antigen. Nature 360: 593-597.
24. Ochoa, M. T., S. Stenger, P. A. Sieling, S. Thoma-Uszynski, S. Sabet, S. Cho, A. M. Krensky, M. Rollinghoff, E. Nunes Sarno, A. E. Burdick, et al. 2001. T-cell release of granulysin contributes to host defense in leprosy. Nat. Med. 7: 174-179.
25. Stenger, S., R. J. Mazzaccaro, K. Uyemura, S. Cho, P. F. Barnes, J. P. Rosat, A. Sette, M. B. Brenner, S. A. Porcelli, B. R. Bloom, and R. L. Modlin. 1997. Differential effects of cytolytic T cell subsets on intracellular infection. Science 276: 1684-1687.
26. Stenger, S., D. A. Hanson, R. Teitelbaum, P. Dewan, K. R. Niazi, C. J. Froelich, T. Ganz, S. Thoma-Uszynski, A. Melian, C. Bogdan, et al. 1998. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282: 121-125.
27. + αβ T cell pool. J. Immunol. 162: 366-371.
28. Ulrichs, T., D. B. Moody, E. Grant, S. H. Kaufmann, and S. A. Porcelli. 2003. T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection. Infect. Immun. 71: 3076-3087.
29. Brennan, P. J., M. Souhrada, B. Ullom, J. K. McClatchy, and M. B. Goren. 1978. Identification of atypical mycobacteria by thin-layer chromatography of their surface antigens. J. Clin. Microbiol. 8: 374-379.
30. Eckstein, T. M., S. Chandrasekaran, S. Mahapatra, M. R. McNeil, D. Chatterjee, C. D. Rithner, P. W. Ryan, J. T. Belisle, and J. M. Inamine. 2006. A major cell wall lipopeptide of Mycobacterium avium subspecies paratuberculosis. J. Biol. Chem. 281: 5209-5215.
31. Hiromatsu, K., C. C. Dascher, K. P. LeClair, M. Sugita, S. T. Furlong, M. B. Brenner, and S. A. Porcelli. 2002. Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens. J. Immunol. 169: 330-339.
32. Dascher, C. C., K. Hiromatsu, X. Xiong, C. Morehouse, G. Watts, G. Liu, D. N. McMurray, K. P. LeClair, S. A. Porcelli, and M. B. Brenner. 2003. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int. Immunol. 15: 915-925.
33. + T lymphocytes specific for Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 95: 270-275.
34. Gansert, J. L., V. Kiessler, M. Engele, F. Wittke, M. Rollinghoff, A. M. Krensky, S. A. Porcelli, R. L. Modlin, and S. Stenger. 2003. Human NKT cells express granulysin and exhibit antimycobacterial activity. J. Immunol. 170: 3154-3161.
35. Jedema, I., N. M. van der Werff, R. M. Barge, R. Willemze, and J. H. Falkenburg. 2004. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103: 2677-2682.
36. Jungblut, P. R., and R. Seifert. 1990. Analysis by high-resolution two-dimensional electrophoresis of differentiation-dependent alterations in cytosolic protein pattern of HL-60 leukemic cells. J. Biochem. Biophys. Methods 21: 47-58.
37. Sieling, P. A., W. Chung, B. T. Duong, P. J. Godowski, and R. L. Modlin. 2003. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 170: 194-200.
38. Rosenkrands, I., E. M. Agger, A. W. Olsen, K. S. Korsholm, C. S. Andersen, K. T. Jensen, and P. Andersen. 2005. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect. Immun. 73: 5817-5826.
39. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
40. + central memory T cells. J. Exp. Med. 200: 725-735.
41. + T cells provides a host defense mechanism against Mycobacterium tuberculosis. J. Immunol. 175: 7474-7483.
42. Brennan, P. J., and P. Draper. 1994. Ultrastructure of mycobacteria. In Tuberculosis: Pathogenesis, Protection and Control. B. R. Bloom, ed. ASM, Washington, D.C., pp. 271-284.
43. Seid, R. C., Jr., and J. C. Sadoff. 1981. Preparation and characterization of detoxified lipopolysaccharide-protein conjugates. J. Biol. Chem. 256: 7305-7310.
44. Shibata, K., A. Hasebe, T. Into, M. Yamada, and T. Watanabe. 2000. The N-terminal lipopeptide of a 44-kDa membrane-bound lipoprotein of Mycoplasma salivarium is responsible for the expression of intercellular adhesion molecule-1 on the cell surface of normal human gingival fibroblasts. J. Immunol. 165: 6538-6544.
45. Hashimoto, M., Y. Asai, and T. Ogawa. 2004. Separation and structural analysis of lipoprotein in a lipopolysaccharide preparation from Porphyromonas gingivalis. Int. Immunol. 16: 1431-1437.
46. Shimizu, T., Y. Kida, and K. Kuwano. 2005. A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-κ-B through TLR1, TLR2, and TLR6. J. Immunol. 175: 4641-4646.
47. Wu, H. C., F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger. 1996. Biosynthesis of lipoproteins. In Escherichia coli and Salmonella typhimurium. C. Neidhardt, ed. ASM, Washington, D.C., pp. 1005-1014.
48. Sutcliffe, I. C., and D. J. Harrington. 2004. Lipoproteins of Mycobacterium tuberculosis: an abundant and functionally diverse class of cell envelope components. FEMS Microbiol. Rev. 28: 645-659.
49. Rezwan, M., T. Grau, A. Tschumi, and P. Sander. 2007. Lipoprotein synthesis in mycobacteria. Microbiology 153: 652-658.
50. Chamberlain, N. R., M. E. Brandt, A. L. Erwin, J. D. Radolf, and M. V. Norgard. 1989. Major integral membrane protein immunogens of Treponema pallidum are proteolipids. Infect. Immun. 57: 2872-2877.
51. Bricker, T. M., M. J. Boyer, J. Keith, R. Watson-McKown, and K. S. Wise. 1988. Association of lipids with integral membrane surface proteins of Mycoplasma hyorhinis. Infect. Immun. 56: 295-301.
52. Weis, J. J., Y. Ma, and L. F. Erdile. 1994. Biological activities of native and recombinant Borrelia burgdorferi outer surface protein A: dependence on lipid modification. Infect. Immun. 62: 4632-4636.
53. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry, III, et al. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. [Published erratum appears in 1998 Nature 396: 190]. Nature 393: 537-544.
54. Aliprantis, A. O., R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 285: 736-739.
55. Brightbill, H. D., D. H. Libraty, S. R. Krutzik, R. B. Yang, J. T. Belisle, J. R. Bleharski, M. Maitland, M. V. Norgard, S. E. Plevy, S. T. Smale, et al. 1999. Host defense mechanisms triggered by microbial lipoproteins through Toll-like receptors. Science 285: 732-736.
56. Noss, E. H., R. K. Pai, T. J. Sellati, J. D. Radolf, J. Belisle, D. T. Golenbock, W. H. Boom, and C. V. Harding. 2001. Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis. J. Immunol. 167: 910-918.
57. Fulton, S. A., S. M. Reba, R. K. Pai, M. Pennini, M. Torres, C. V. Harding, and W. H. Boom. 2004. Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein. Infect. Immun. 72: 2101-2110.
58. Lopez, M., L. M. Sly, Y. Luu, D. Young, H. Cooper, and N. E. Reiner. 2003. The 19-kDa Mycobacterium tuberculosis protein induces macrophage apoptosis through Toll-like receptor-2. J. Immunol. 170: 2409-2416.
59. Hertz, C. J., S. M. Kiertscher, P. J. Godowski, D. A. Bouis, M. V. Norgard, M. D. Roth, and R. L. Modlin. 2001. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J. Immunol. 166: 2444-2450.
60. Neufert, C., R. K. Pai, E. H. Noss, M. Berger, W. H. Boom, and C. V. Harding. 2001. Mycobacterium tuberculosis 19-kDa lipoprotein promotes neutrophil activation. J. Immunol. 167: 1542-1549.
61. Thoma-Uszynski, S., S. Stenger, O. Takeuchi, M. T. Ochoa, M. Engele, P. A. Sieling, P. F. Barnes, M. Rollinghoff, P. L. Bolcskei, M. Wagner, et al. 2001. Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science 291: 1544-1547.
62. Liu, P. T., S. Stenger, H. Li, L. Wenzel, B. H. Tan, S. R. Krutzik, M. T. Ochoa, J. Schauber, K. Wu, C. Meinken, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
63. Liu, P. T., S. Stenger, D. H. Tang, and R. L. Modlin. 2007. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 179: 2060-2063.
64. Stewart, G. R., K. A. Wilkinson, S. M. Newton, S. M. Sullivan, O. Neyrolles, J. R. Wain, J. Patel, K. L. Pool, D. B. Young, and R. J. Wilkinson. 2005. Effect of deletion or overexpression of the 19-kilodalton lipoprotein Rv3763 on the innate response to Mycobacterium tuberculosis. Infect. Immun. 73: 6831-6837.
65. Yeremeev, V. V., G. R. Stewart, O. Neyrolles, K. Skrabal, V. G. Avdienko, A. S. Apt, and D. B. Young. 2000. Deletion of the 19 kDa antigen does not alter the protective efficacy of BCG. Tuber. Lung Dis. 80: 243-247.
66. Rao, V., N. Dhar, H. Shakila, R. Singh, A. Khera, R. Jain, M. Naseema, C. N. Paramasivan, P. R. Narayanan, V. D. Ramanathan, and A. K. Tyagi. 2005. Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype. Scand. J. Immunol. 61: 410-417.
67. Sassetti, C. M., and E. J. Rubin. 2003. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. USA 100: 12989-12994.
68. Hovav, A. H., L. Davidovitch, G. Nussbaum, J. Mullerad, Y. Fishman, and H. Bercovier. 2004. Mitogenicity of the recombinant mycobacterial 27-kilodalton lipoprotein is not connected to its antiprotective effect. Infect. Immun. 72: 3383-3390.
69. Hovav, A. H., J. Mullerad, L. Davidovitch, Y. Fishman, F. Bigi, A. Cataldi, and H. Bercovier. 2003. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect. Immun. 71: 3146-3154.
70. Hovav, A. H., J. Mullerad, A. Maly, L. Davidovitch, Y. Fishman, and H. Bercovier. 2006. Aggravated infection in mice co-administered with Mycobacterium tuberculosis and the 27-kDa lipoprotein. Microbes Infect. 8: 1750-1757.
71. Bigi, F., A. Gioffre, L. Klepp, M. P. Santangelo, A. Alito, K. Caimi, V. Meikle, M. Zumarraga, O. Taboga, M. I. Romano, and A. Cataldi. 2004. The knockout of the lprG-Rv1410 operon produces strong attenuation of Mycobacterium tuberculosis. Microbes Infect. 6: 182-187.
72. Banaiee, N., E. Z. Kincaid, U. Buchwald, W. R. Jacobs, Jr., and J. D. Ernst. 2006. Potent inhibition of macrophage responses to IFN-γ by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2. J. Immunol. 176: 3019-3027.
73. Sander, P., M. Rezwan, B. Walker, S. K. Rampini, R. M. Kroppenstedt, S. Ehlers, C. Keller, J. R. Keeble, M. Hagemeier, M. J. Colston, et al. 2004. Lipoprotein processing is required for virulence of Mycobacterium tuberculosis. Mol. Microbiol. 52: 1543-1552.
74. Vordemeier, H. M., D. P. Harris, E. Roman, R. Lathigra, C. Moreno, and J. Ivanyi. 1991. Identification of T cell stimulatory peptides from the 38-kDa protein of Mycobacterium tuberculosis. J. Immunol. 147: 1023-1029.
75. Oftung, F., H. G. Wiker, A. Deggerdal, and A. S. Mustafa. 1997. A novel mycobacterial antigen relevant to cellular immunity belongs to a family of secreted lipoproteins. Scand. J. Immunol. 46: 445-451.
76. Bigi, F., C. Espitia, A. Alito, M. Zumarraga, M. I. Romano, S. Cravero, and A. Cataldi. 1997. A novel 27 kDa lipoprotein antigen from Mycobacterium bovis. Microbiology 143(Pt. 11): 3599-3605.
77. da Fonseca, D. P., D. Joosten, R. van der Zee, D. L. Jue, M. Singh, H. M. Vordermeier, H. Snippe, and A. F. Verheul. 1998. Identification of new cytotoxic T-cell epitopes on the 38-kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides. Infect. Immun. 66: 3190-3197.
78. Mohagheghpour, N., D. Gammon, L. M. Kawamura, A. van Vollenhoven, C. J. Benike, and E. G. Engleman. 1998. CTL response to Mycobacterium tuberculosis: identification of an immunogenic epitope in the 19-kDa lipoprotein. J. Immunol. 161: 2400-2406.
79. Deres, K., H. Schild, K. H. Wiesmuller, G. Jung, and H. G. Rammensee. 1989. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342: 561-564.
80. Rees, A. D., A. Faith, E. Roman, J. Ivanyi, K. H. Wiesmuller, and C. Moreno. 1993. The effect of lipoylation on CD4 T-cell recognition of the 19,000 MW Mycobacterium tuberculosis antigen. Immunology 80: 407-414.
81. Fonseca, D. P., D. Joosten, H. Snippe, and A. F. Verheul. 2000. Evaluation of T-cell responses to peptides and lipopeptides with MHC class I binding motifs derived from the amino acid sequence of the 19-kDa lipoprotein of Mycobacterium tuberculosis. Mol. Immunol. 37: 413-422.
82. Beekman, N. J., W. M. Schaaper, G. I. Tesser, K. Dalsgaard, S. Kamstrup, J. P. Langeveld, R. S. Boshuizen, and R. H. Meloen. 1997. Synthetic peptide vaccines: palmitoylation of peptide antigens by a thioester bond increases immunogenicity. J. Pept. Res. 50: 357-364.
83. Loing, E., M. Andrieu, K. Thiam, D. Schorner, K. H. Wiesmuller, A. Hosmalin, G. Jung, and H. Gras-Masse. 2000. Extension of HLA-A*0201- restricted minimal epitope by N ε-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells. J. Immunol. 164: 900-907.
84. Stittelaar, K. J., P. Hoogerhout, W. Ovaa, R. R. van Binnendijk, M. C. Poelen, P. Roholl, C. A. van Els, A. D. Osterhaus, and E. J. Wiertz. 2001. In vitro processing and presentation of a lipidated cytotoxic T-cell epitope derived from measles virus fusion protein. Vaccine 20: 249-261.
85. Neyrolles, O., K. Gould, M. P. Gares, S. Brett, R. Janssen, P. O'Gaora, J. L. Herrmann, M. C. Prevost, E. Perret, J. E. Thole, and D. Young. 2001. Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria. J. Immunol. 166: 447-457.
86. Robinson, J. H., M. C. Case, and C. G. Brooks. 1992. Palmitic acid conjugation of a protein antigen enhances major histocompatibility complex class II-restricted presentation to T cells. Immunology 76: 593-598.
87. Engelhard, V. H., M. Altrich-Vanlith, M. Ostankovitch, and A. L. Zarling. 2006. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol. 18: 92-97.
88. Stenger, S. 2001. Cytolytic T cells in the immune response to mycobacterium tuberculosis. Scand. J. Infect. Dis. 33: 483-487.
89. Lorgat, F., M. M. Keraan, P. T. Lukey, and S. R. Ress. 1992. Evidence for in vivo generation of cytotoxic T cells: PPD-stimulated lymphocytes from tuberculous pleural effusions demonstrate enhanced cytotoxicity with accelerated kinetics of induction. Am. Rev. Respir. Dis. 145: 418-423.
90. + T cells that are cytotoxic and display Th1-like cytokine secretion profile: heterogeneity in cytotoxic activity and cytokine secretion levels. Eur. J. Immunol. 23: 2189-2195.
91. + cytotoxic T cell clones: a novel potentially immunoregulatory T-T cell interaction in man. J. Exp. Med. 171: 2011-2024.
92. + cytotoxic T lymphocytes. Exp. Hematol. 33: 811-818.
93. + CTL directed against herpes simplex virus-infected cells. J. Immunol. 162: 6100-6106.
94. + T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon γ and nitric oxide synthase 2. J. Exp. Med. 192: 347-358.
95. Iezzi, G., D. Scheidegger, and A. Lanzavecchia. 2001. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J. Exp. Med. 193: 987-993.
96. Mitra, D. K., S. K. Sharma, A. K. Dinda, M. S. Bindra, B. Madan, and B. Ghosh. 2005. Polarized helper T cells in tubercular pleural effusion: phenotypic identity and selective recruitment. Eur. J. Immunol. 35: 2367-2375.
97. Lande, R., E. Giacomini, T. Grassi, M. E. Remoli, E. Iona, M. Miettinen, I. Julkunen, and E. M. Coccia. 2003. IFN-αβ released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: selective recruitment of NK and activated T cells. J. Immunol. 170: 1174-1182.
98. Seiler, P., P. Aichele, S. Bandermann, A. E. Hauser, B. Lu, N. P. Gerard, C. Gerard, S. Ehlers, H. J. Mollenkopf, and S. H. Kaufmann. 2003. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur. J. Immunol. 33: 2676-2686.
99. Schrum, S., P. Probst, B. Fleischer, and P. F. Zipfel. 1996. Synthesis of the CC-chemokines MIP-1β, MIP-1 , and RANTES is associated with a type 1 immune response. J. Immunol. 157: 3598-3604.
100. Dorner, B. G., A. Scheffold, M. S. Rolph, M. B. Huser, S. H. Kaufmann, A. Radbruch, I. E. Flesch, and R. A. Kroczek. 2002. MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines. Proc. Natl. Acad. Sci. USA 99: 6181-6186.